Translocation (8;12)(q13;p13) during disease progression in acute myelomonocytic leukemia with t(11;19)(q23;p13.1). 2002

Katsuya Yamamoto, and Kaoru Nagata, and Yoshito Tsurukubo, and Koichi Inagaki, and Ryoichi Ono, and Tomohiko Taki, and Yasuhide Hayashi, and Hiroyuki Hamaguchi
Department of Hematology, Musashino Red Cross Hospital, 1-26-1 Kyonan-cho, Musashino, 180-8610, Tokyo, Japan.

We report here the first case of acute myelomonocytic leukemia (AMMoL) with both t(8;12)(q13;p13) and t(11;19)(q23;p13.1). A 75-year-old woman was initially diagnosed as having AMMoL with t(11;19) (q23;p13) as a sole abnormality. At the second relapse, G-banding analysis of the bone marrow cells showed 46,XX,t(11;19)(q23;p13)/46,XX,t(8;12)(q13;p13),t(11;19)(q23;p13). Fluorescence in situ hybridization analysis with chromosome-specific painting probes confirmed both the der(8)t(8;12) and the der(12)t(8;12). Reverse transcription-polymerase chain reaction analysis detected the MLL/ELL fusion transcript, indicating that the breakpoint on chromosome 19 was 19p13.1. Leukemic cells at the second relapse were positive for CD2, CD13, CD33, and CD34 but negative for CD14 and HLA-DR. The patient died within 2 months after a subclone with t(8;12)(q13;p13) had appeared. In the literature, t(8;12)(q12;p13) has been observed in two cases of myelodysplastic syndrome and one case of acute myeloblastic leukemia. Our results indicated that t(8;12)(q13;p13) may be one of the recurrent aberrations in myeloid malignancies, although molecular heterogeneity of the breakpoints might exist. Furthermore, it is suggested that t(8;12)(q13;p13) may play an important role in the progression of the disease and lead to the poor prognosis.

UI MeSH Term Description Entries
D007621 Karyotyping Mapping of the KARYOTYPE of a cell. Karyotype Analysis Methods,Analysis Method, Karyotype,Analysis Methods, Karyotype,Karyotype Analysis Method,Karyotypings,Method, Karyotype Analysis,Methods, Karyotype Analysis
D008969 Molecular Sequence Data Descriptions of specific amino acid, carbohydrate, or nucleotide sequences which have appeared in the published literature and/or are deposited in and maintained by databanks such as GENBANK, European Molecular Biology Laboratory (EMBL), National Biomedical Research Foundation (NBRF), or other sequence repositories. Sequence Data, Molecular,Molecular Sequencing Data,Data, Molecular Sequence,Data, Molecular Sequencing,Sequencing Data, Molecular
D009363 Neoplasm Proteins Proteins whose abnormal expression (gain or loss) are associated with the development, growth, or progression of NEOPLASMS. Some neoplasm proteins are tumor antigens (ANTIGENS, NEOPLASM), i.e. they induce an immune reaction to their tumor. Many neoplasm proteins have been characterized and are used as tumor markers (BIOMARKERS, TUMOR) when they are detectable in cells and body fluids as monitors for the presence or growth of tumors. Abnormal expression of ONCOGENE PROTEINS is involved in neoplastic transformation, whereas the loss of expression of TUMOR SUPPRESSOR PROTEINS is involved with the loss of growth control and progression of the neoplasm. Proteins, Neoplasm
D010445 Peptide Elongation Factors Protein factors uniquely required during the elongation phase of protein synthesis. Elongation Factor,Elongation Factors, Peptide,Factor, Elongation,Factors, Peptide Elongation
D011495 Histone-Lysine N-Methyltransferase An enzyme that catalyzes the methylation of the epsilon-amino group of lysine residues in proteins to yield epsilon mono-, di-, and trimethyllysine. Protein Lysine Methyltransferase,Protein Methylase III,Protein Methyltransferase III,Histone-Lysine Methyltransferase,Histone Lysine Methyltransferase,Histone Lysine N Methyltransferase,Methyltransferase, Histone-Lysine,Methyltransferase, Protein Lysine,N-Methyltransferase, Histone-Lysine
D011519 Proto-Oncogenes Normal cellular genes homologous to viral oncogenes. The products of proto-oncogenes are important regulators of biological processes and appear to be involved in the events that serve to maintain the ordered procession through the cell cycle. Proto-oncogenes have names of the form c-onc. Proto-Oncogene,Proto Oncogene,Proto Oncogenes
D011993 Recombinant Fusion Proteins Recombinant proteins produced by the GENETIC TRANSLATION of fused genes formed by the combination of NUCLEIC ACID REGULATORY SEQUENCES of one or more genes with the protein coding sequences of one or more genes. Fusion Proteins, Recombinant,Recombinant Chimeric Protein,Recombinant Fusion Protein,Recombinant Hybrid Protein,Chimeric Proteins, Recombinant,Hybrid Proteins, Recombinant,Recombinant Chimeric Proteins,Recombinant Hybrid Proteins,Chimeric Protein, Recombinant,Fusion Protein, Recombinant,Hybrid Protein, Recombinant,Protein, Recombinant Chimeric,Protein, Recombinant Fusion,Protein, Recombinant Hybrid,Proteins, Recombinant Chimeric,Proteins, Recombinant Fusion,Proteins, Recombinant Hybrid
D002871 Chromosome Banding Staining of bands, or chromosome segments, allowing the precise identification of individual chromosomes or parts of chromosomes. Applications include the determination of chromosome rearrangements in malformation syndromes and cancer, the chemistry of chromosome segments, chromosome changes during evolution, and, in conjunction with cell hybridization studies, chromosome mapping. Banding, Chromosome,Bandings, Chromosome,Chromosome Bandings
D002874 Chromosome Mapping Any method used for determining the location of and relative distances between genes on a chromosome. Gene Mapping,Linkage Mapping,Genome Mapping,Chromosome Mappings,Gene Mappings,Genome Mappings,Linkage Mappings,Mapping, Chromosome,Mapping, Gene,Mapping, Genome,Mapping, Linkage,Mappings, Chromosome,Mappings, Gene,Mappings, Genome,Mappings, Linkage
D002880 Chromosomes, Human, Pair 11 A specific pair of GROUP C CHROMOSOMES of the human chromosome classification. Chromosome 11

Related Publications

Katsuya Yamamoto, and Kaoru Nagata, and Yoshito Tsurukubo, and Koichi Inagaki, and Ryoichi Ono, and Tomohiko Taki, and Yasuhide Hayashi, and Hiroyuki Hamaguchi
December 1991, Leukemia,
Katsuya Yamamoto, and Kaoru Nagata, and Yoshito Tsurukubo, and Koichi Inagaki, and Ryoichi Ono, and Tomohiko Taki, and Yasuhide Hayashi, and Hiroyuki Hamaguchi
November 1986, Cancer genetics and cytogenetics,
Katsuya Yamamoto, and Kaoru Nagata, and Yoshito Tsurukubo, and Koichi Inagaki, and Ryoichi Ono, and Tomohiko Taki, and Yasuhide Hayashi, and Hiroyuki Hamaguchi
January 1993, Medical and pediatric oncology,
Katsuya Yamamoto, and Kaoru Nagata, and Yoshito Tsurukubo, and Koichi Inagaki, and Ryoichi Ono, and Tomohiko Taki, and Yasuhide Hayashi, and Hiroyuki Hamaguchi
December 2017, International journal of hematology,
Katsuya Yamamoto, and Kaoru Nagata, and Yoshito Tsurukubo, and Koichi Inagaki, and Ryoichi Ono, and Tomohiko Taki, and Yasuhide Hayashi, and Hiroyuki Hamaguchi
July 2016, Leukemia,
Katsuya Yamamoto, and Kaoru Nagata, and Yoshito Tsurukubo, and Koichi Inagaki, and Ryoichi Ono, and Tomohiko Taki, and Yasuhide Hayashi, and Hiroyuki Hamaguchi
May 1993, Japanese journal of cancer research : Gann,
Katsuya Yamamoto, and Kaoru Nagata, and Yoshito Tsurukubo, and Koichi Inagaki, and Ryoichi Ono, and Tomohiko Taki, and Yasuhide Hayashi, and Hiroyuki Hamaguchi
July 2006, Cancer genetics and cytogenetics,
Katsuya Yamamoto, and Kaoru Nagata, and Yoshito Tsurukubo, and Koichi Inagaki, and Ryoichi Ono, and Tomohiko Taki, and Yasuhide Hayashi, and Hiroyuki Hamaguchi
July 2008, Cancer genetics and cytogenetics,
Katsuya Yamamoto, and Kaoru Nagata, and Yoshito Tsurukubo, and Koichi Inagaki, and Ryoichi Ono, and Tomohiko Taki, and Yasuhide Hayashi, and Hiroyuki Hamaguchi
July 2015, Cureus,
Katsuya Yamamoto, and Kaoru Nagata, and Yoshito Tsurukubo, and Koichi Inagaki, and Ryoichi Ono, and Tomohiko Taki, and Yasuhide Hayashi, and Hiroyuki Hamaguchi
February 2003, Cancer genetics and cytogenetics,
Copied contents to your clipboard!